Comparing the impact of atezolizumab plus bevacizumab and lenvatinib on the liver function in hepatocellular carcinoma patients: A mixed‐effects regression model approach

This retrospective study compared the impact of atezolizumab plus bevacizumab (Atez/Bev) and lenvatinib (LEN) on the liver function in patients with hepatocellular carcinoma.

• Publication year

  2023

• Venue

  Cancer Medicine

• Publication date

  2023-11-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cam4.6726PMID 37987139PMCID 10757119
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparing the impact of atezolizumab plus bevacizumab and lenvatinib on the liver function in hepatocellular carcinoma patients: A mixed‐effects regression model approach

  2023cited by this paper
• Real world data of systemic therapy for hepatocellular carcinoma in Japan: HERITAGE study.

  2023cited by this paper
• Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function.

  2022cited by this paper
• Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.

  2022cited by this paper
• Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update

  2021cited by this paper
• BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update.

  2021influential reference
• Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience

  2021cited by this paper
• NASH limits anti-tumour surveillance in immunotherapy-treated HCC

  2021cited by this paper
• Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.

  2020cited by this paper
• Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.

  2020cited by this paper
• Liver Function Changes in Patients with Hepatocellular Carcinoma Treated with Lenvatinib: Predictive Factors of Progression to Child-Pugh Class B, the Formation of Ascites and the Candidates for the Post-Progression Treatment

  2020cited by this paper
• Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis.

  2020cited by this paper
• Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline.

  2020cited by this paper
• Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma

  2019cited by this paper
• Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

  2018cited by this paper
• Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function

  2017cited by this paper
• Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade.

  2015cited by this paper
• Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models

  2014cited by this paper
• Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage

  2014cited by this paper
• Investigation of the freely available easy-to-use software ‘EZR' for medical statistics

  2012cited by this paper
• FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis

  2011cited by this paper
• Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase

  2008cited by this paper
• Hepatology

  2003cited by this paper

• Liver function dynamics in advanced hepatocellular carcinoma receiving immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization

  2025cites this paper
• Future perspectives on immunotherapy for hepatocellular carcinoma

  2025cites this paper
• Comparative effectiveness of immunotherapy versus lenvatinib in advanced hepatocellular carcinoma: A real-world analysis using target trial emulation.

  2025cites this paper
• Efficacy and Safety of Lenvatinib versus Atezolizumab Plus Bevacizumab in the Treatment of Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

  2025influential citation
• Reliable Performance of mALBI Grade‐Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First‐Line Treatment: Comparative Analysis of 13 Risk Models

  2025cites this paper
• Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real‑world practice

  2024cites this paper
• Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: A comparative analysis in a European real-world cohort

  2024cites this paper
• Comparing the impact of atezolizumab plus bevacizumab and lenvatinib on the liver function in hepatocellular carcinoma patients: A mixed‐effects regression model approach

  2023cites this paper